AXGN Strangle Strategy
AXGN (AxoGen, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues.
AXGN (AxoGen, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $2.39B, a beta of 1.12 versus the broader market, a 52-week range of 10.5-46, average daily share volume of 1.2M, a public-listing history dating back to 1986, approximately 451 full-time employees. These structural characteristics shape how AXGN stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.12 places AXGN roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on AXGN?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current AXGN snapshot
As of June 29, 2026, spot at $44.84, ATM IV 49.50%, IV rank 10.57%, expected move 14.19%. The strangle on AXGN below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on AXGN specifically: AXGN IV at 49.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a AXGN strangle, with a market-implied 1-standard-deviation move of approximately 14.19% (roughly $6.36 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AXGN expiries trade a higher absolute premium for lower per-day decay. Position sizing on AXGN should anchor to the underlying notional of $44.84 per share and to the trader's directional view on AXGN stock.
AXGN strangle setup
The AXGN strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AXGN near $44.84, the first option leg uses a $47.08 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AXGN chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AXGN shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $47.08 | N/A |
| Buy 1 | Put | $42.60 | N/A |
AXGN strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
AXGN strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on AXGN. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on AXGN
Strangles on AXGN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AXGN chain.
AXGN thesis for this strangle
The market-implied 1-standard-deviation range for AXGN extends from approximately $38.48 on the downside to $51.20 on the upside. A AXGN long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current AXGN IV rank near 10.57% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AXGN at 49.50%. As a Healthcare name, AXGN options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AXGN-specific events.
AXGN strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AXGN positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AXGN alongside the broader basket even when AXGN-specific fundamentals are unchanged. Always rebuild the position from current AXGN chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on AXGN?
- A strangle on AXGN is the strangle strategy applied to AXGN (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With AXGN stock trading near $44.84, the strikes shown on this page are snapped to the nearest listed AXGN chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are AXGN strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the AXGN strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 49.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a AXGN strangle?
- The breakeven for the AXGN strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current AXGN market-implied 1-standard-deviation expected move is approximately 14.19%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on AXGN?
- Strangles on AXGN are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the AXGN chain.
- How does current AXGN implied volatility affect this strangle?
- AXGN ATM IV is at 49.50% with IV rank near 10.57%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.